Results Presented at Heart Rhythm Society from ASA Plavix Study Evaluating Boston Scientific Left Atrial Appendage Closure Device NATICK and BOSTON, Mass., Boston Scientific Corporation announces ...

Milestone Marks Next Step Toward FDA Submission for Stroke Reduction Device for Patients with Atrial Fibrillation NATICK, Mass. -- Boston Scientific Corporation has completed enrollment in the PREVAIL ...

MARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary ...

(Updated) SAN FRANCISCO, California — Preliminary data from the PREVAIL study of the Watchman (AtriTech/Boston Scientific) device for the prevention of stroke and systemic embolism in patients with ...

The newer-generation Watchman device was associated with sustained safety and efficacy out to 2 years when implanted in people at high thromboembolic risk, the PINNACLE FLX IDE study group reported.

Boston Scientific has won a nod from FDA for the latest generation of the Watchman Left Atrial Appendage Closure (LAAC) technology. Dubbed the Watchman FLX, the technology is designed to advance ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Rates of patency and device-related thrombus were ...

Boston Scientific Corp.’s OPTION study demonstrated left atrial appendage closure with the Watchman Flx device reduced risk of stroke compared to management with direct oral anticoagulants or warfarin ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: I am a 70-year old woman with a prior history of ...

CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints PR Newswire ...